A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.
A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.